William K. McVicar - 03 Jan 2023 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Director
Signature
/s/ Robert Hadfield, Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 16:44:25 UTC
Previous filing
07 Jun 2022
Next filing
22 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $0 +1,440 +414% $0.000000 1,788 03 Jan 2023 Direct F1
holding SLRX Common Stock 1,062 03 Jan 2023 McVicar Family Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024